AKT1 and diabetic kidney disease: Mechanistically, Tripterygium wilfordii, a source of celastrol, likely exerts its therapeutic effects—including anti-inflammatory and antioxidative activities—by suppressing the phosphorylation of NF-κB and AKT1 signaling pathways, thereby mitigating pathological processes linked to inflammation and DKD progression.